SVG103 (Paxalisib)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SVG103 (Paxalisib), covering 2025-12-23 to 2025-12-23. Get the full timeline:
Most recent: Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME) [Phase 1, Phase 2]